# SGMT catalysts: Sagimet Biosciences Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sgmt/catalysts

> Sagimet Biosciences Inc. (SGMT) has 5 upcoming catalysts. The next is the denifanstat primary completion, August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Sagimet Biosciences Inc. |
| Ticker | SGMT (Nasdaq) |
| SEC CIK | 1400118 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sgmt |

## Cash runway

Cash $275.8M as of 2026-09-30; quarterly burn $12.1M; about 68.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-456948).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | completed, positive | "In May 2023, Ascletis Pharma, announced positive topline results with the achievement of primary and key secondary endpoints in a Phase 2 clinical trial in 179 patients with moderate to severe acne vulgaris in China." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/sgmt-20241231x10k.htm)) |
| Jan 2024 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | completed, positive | "January 2024, Sagimet announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-1.htm)) |
| November 14, 2024 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_ex99-1.htm)) |
| Mar 2025 | [TVB-3567 trial start](https://sec-api.dev/pdufa/tvb-3567) | SGMT |  | completed | "Sagimet's second FASN inhibitor, TVB-3567, a potent and selective small molecule FASN inhibitor, received IND clearance in March 2025, and in June 2025 the Company initiated a first-in-human Phase 1 clinical trial of TVB-3567 for development of an acne indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1400118/000155837025011301/sgmt-20250630x10q.htm)) |
| March 12, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Calif., March 12, 2025 - Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-1.htm)) |
| Q2 2025 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "Topline results expected in 2Q2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-2.htm)) |
| May 8, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-1.htm)) |
| Jun 2025 | [TVB-3567 trial start](https://sec-api.dev/pdufa/tvb-3567) | SGMT |  | completed | "Potential Clinical Development Program for TVB-3567 in Acne Phase 1 clinical trial initiated in June 2025 Goal: Initiate Phase 2 clinical trial in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm)) |
| Jun 2025 | [Denifanstat trial start](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | completed | "Phase 2 trial design anticipated to be informed by the results of the Phase 1 trial, expect a 12 - week dose ranging study in moderate to severe acne patients with lesion reduction, treatment success (IGA) as endpoints Phase 1 trial initiated in June 2025 Goal to initiate Phase 2 trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_ex99-2.htm)) |
| 2H 2025 | [TVB-3567 trial start](https://sec-api.dev/pdufa/tvb-3567) | SGMT |  | scheduled | "The IND clearance allows us to initiate a first-in-human Phase 1 clinical trial of TVB-3567 for development of an acne indication, which we expect to initiate in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1400118/000155837025006836/sgmt-20250331x10q.htm)) |
| 2H 2025 | [Denifanstat trial start](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "Additionally, pending consultation with regulatory authorities, we plan to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of our FASN inhibitor denifanstat and resmetirom in the second half of 2025 as the first step towards development of a combination product for patients living with MASH." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm)) |
| August 13, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports Second Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm)) |
| late 2025 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_ex99-1.htm)) |
| Sep 2025 | [Denifanstat trial start](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | completed | "September 2025, Sagimet announced that it has dosed the first participants in a Phase 1 PK trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_ex99-1.htm)) |
| November 13, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Calif., November 13, 2025 - Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-1.htm)) |
| Jan 2026 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT | moderate to severe acne in China | completed, positive | "January 2026, positive topline results were reported in the open-label Phase 3 trial (n=240) evaluating the long-term safety of 50 mg once-daily denifanstat in patients with moderate to severe acne in China by Sagimet's license partner Ascletis Bioscience Co." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_ex99-2.htm)) |
| 1H 2026 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "We anticipate topline data from this Phase 1 PK trial to be available in the first half of 2026 and plan to use it to inform the optimal dose levels of denifanstat and resmetirom to evaluate in a Phase 2 combination proof-of-concept efficacy trial in F4 MASH patients, subject to consultation with regulatory authorities." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1400118/000110465925110846/sgmt-20250930x10q.htm)) |
| March 11, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_ex99-1.htm)) |
| May 12, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm)) |
| August 11, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435dex991.htm)) |
| late 2026 | [Denifanstat trial start](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "Upon completion of Phase 1 clinical trial, plan to consult with regulatory authorities regarding Phase 2 clinical trial design, with goal of initiating Phase 2 clinical trial in 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526309334/d141539dex991.htm)) |
| late 2026 | [TVB-3567 trial start](https://sec-api.dev/pdufa/tvb-3567) | SGMT |  | scheduled | "Upon completion of the Phase 1 clinical trial of TVB-3567, subject to consultation with regulatory authorities, Sagimet plans to initiate a Phase 2 clinical trial with TVB-3567 in moderate to severe acne patients in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm)) |
| Oct 2026 | [Denifanstat trial start](https://sec-api.dev/pdufa/denifanstat) | SGMT | moderate to severe acne in Oct 2026 | completed | "First patient dosed in AURORA Phase 3 clinical trial in the US for patients with moderate to severe acne in Oct 2026; topline results expected in 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm)) |
| November 12, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm)) |
| August 2027 | [Denifanstat primary completion](https://sec-api.dev/pdufa/denifanstat) | SGMT | Acne Vulgaris | scheduled | "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07863193)) |
| Aug to Nov 2027 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT | Acne Vulgaris | scheduled | "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07863193)) |
| 2028 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | "Combined with our existing cash balance, we are well capitalized to fund our programs through 2028 including data readout of our planned denifanstat Phase 3 clinical trial in moderate to severe acne."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm)) |
| mid-2029 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | ""With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm)) |
| mid-2029 | [Denifanstat NDA/BLA submission](https://sec-api.dev/pdufa/denifanstat) | SGMT |  | scheduled | ""With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm)) |

## Drugs

- [Denifanstat](https://sec-api.dev/pdufa/denifanstat): moderate to severe acne in oct 2026, moderate to severe acne in china, moderate to severe acne in oct 2026 november 2026 29, Acne Vulgaris
- [TVB-3567](https://sec-api.dev/pdufa/tvb-3567): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sgmt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SGMT catalysts: Sagimet Biosciences Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sgmt/catalysts

```bibtex
@misc{secapidev_companies_sgmt_catalysts_20261116,
  title        = {SGMT catalysts: Sagimet Biosciences Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sgmt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sgmt_catalysts_20261116","title":"SGMT catalysts: Sagimet Biosciences Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sgmt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
